Open Access<p>Safety And Tolerability Of Extended-Release Guaifenesin In Patients With Cough, Thickened Mucus And Chest Congestion Associated With Upper Respiratory Tract Infection</p>
Author(s) -
Sanjay Tripathi,
Ashish Nikhare,
Gaurav Sharma,
Tim Shea,
Helmut H. Albrecht
Publication year - 2019
Publication title -
drug, healthcare and patient safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 24
ISSN - 1179-1365
DOI - 10.2147/dhps.s222109
Subject(s) - medicine , tolerability , adverse effect , expectorant , mucus , respiratory tract infections , gastroenterology , anesthesia , respiratory system , pharmacology , ecology , biology
An extended-release (ER) formulation of the expectorant guaifenesin has recently been launched in India for the treatment of productive cough accompanied by mucus (phlegm). Although the safety profile of ER guaifenesin marketed in the USA is well documented, there were limited safety data available in the Indian population. The aim of this study was to further elucidate the safety profile of ER guaifenesin in patients with acute upper respiratory tract infection (URTI).